




Instance: composition-en-8a06156d853d45b0ba99d89b9f448d89
InstanceOf: CompositionUvEpi
Title: "Composition for visudyne Package Leaflet"
Description:  "Composition for visudyne Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mped801563fb8e34f1b3dd54789546d247)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - visudyne"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Visudyne is and what it is used for </li>
<li>What you need to know before you are given Visudyne </li>
<li>How Visudyne is used </li>
<li>Possible side effects </li>
<li>How to store Visudyne </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What visudyne is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What visudyne is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Visudyne is 
Visudyne contains the active substance verteporfin, which is activated by light from a laser in a 
treatment called photodynamic therapy. When you are given an infusion of Visudyne, it is distributed 
within your body through the blood vessels, including the blood vessels at the back of the eye. When 
the laser light is shone into the eye, Visudyne is activated. </p>
<p>What Visudyne is used for 
Visudyne is used to treat the wet form of age-related macular degeneration and pathological myopia. </p>
<p>These diseases lead to vision loss. Vision loss is caused by new blood vessels (choroidal 
neovascularisation) that damage the retina (the light-sensitive membrane that lines the back of the 
eye). There are two types of choroidal neovascularisation: classic and occult. </p>
<p>Visudyne is used for the treatment of predominantly classic choroidal neovascularisation in adults 
with age-related macular degeneration, and also for the treatment of all types of choroidal 
neovascularisation in adults with pathological myopia. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take visudyne"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take visudyne"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should not be given Visudyne 
- if you are allergic to verteporfin or any of the other ingredients of this medicine (listed in 
section 6). 
- if you have porphyria (a rare condition that may increase sensitivity to light). 
- if you have any severe liver problems. 
If any of these apply to you, tell your doctor. You should not be given Visudyne. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before you are given Visudyne 
- If you experience any infusion-related problems or symptoms during or following the 
treatment such as chest pain, sweating, dizziness, rash, breathlessness, flushing, irregular heart 
beat or seizure, please tell your doctor or nurse immediately, as the infusion may need to be 
stopped and your condition may need to be treated urgently. Infusion-related problems may also 
include sudden loss of consciousness. 
- If you have any liver problems or a blockage of your bile duct, please tell your doctor before 
starting Visudyne therapy. 
- If, during the infusion, Visudyne goes outside the vein, and especially if the affected area is 
exposed to light, this can cause pain, swelling, blistering and a change in skin colour in the area 
of the leakage. If this happens, the infusion needs to be stopped and the skin treated with cold 
compresses and thoroughly protected from light until the skin colour returns to normal. You 
may need to take a painkiller. 
- You will be sensitive to bright light for 48 hours after the infusion. During that time, avoid 
exposure to direct sunlight, bright indoor lights such as in tanning salons, bright halogen 
lighting, high power lighting as used by surgeons or dentists, or light from light-emitting 
medical devices such as pulse oximeters (used to measure oxygen in blood). If you have to go 
outdoors during daylight in the first 48 hours after treatment, you must protect your skin and 
eyes by wearing protective clothing and dark sunglasses. Sunscreens offer no protection. 
Normal indoor lighting is safe. 
- Do not stay in the dark because exposure to normal indoor lighting will help your body to 
eliminate Visudyne more quickly. 
- If you experience any eye problems after the treatment, such as a vision loss, talk to your 
doctor. </p>
<p>Other medicines and Visudyne 
Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Tell your doctor or pharmacist if you are taking any of the following medicines, as they may increase 
your sensitivity to light:</p>
<ul>
<li>tetracyclines or sulphonamides (used to treat bacterial infection), </li>
<li>phenothiazines (used to treat psychiatric disorders, or nausea and vomiting), </li>
<li>sulfonylurea (used to treat diabetes), </li>
<li>medicines used to lower blood sugar, </li>
<li>thiazide diuretics (used to reduce high blood pressure), </li>
<li>griseofulvin (used to treat fungal infection), </li>
<li>calcium channel blockers (used to treat high blood pressure, angina and abnormal heart 
rhythms), </li>
<li>antioxidants such as beta-carotene or medicines that can remove or inactivate free radicals (such 
as dimethylsulfoxide (DMSO), formate, mannitol and alcohol), </li>
<li>vasodilators (used to widen blood vessels resulting from smooth muscle relaxation), </li>
<li>or, if you are undergoing radiation therapy, </li>
</ul>
<p>Pregnancy and breast-feeding 
- There is very little experience of using Visudyne in pregnant women. It is important to tell your 
doctor if you are pregnant, if you think you may be pregnant or if you plan to become pregnant. 
You should only be given Visudyne if your doctor considers it absolutely essential. 
- Verteporfin passes into human milk in low amounts. Please tell your doctor if you are 
breastfeeding. He/she will decide whether you should be given Visudyne. It is recommended 
that, if you are given Visudyne, you do not breastfeed for 48 hours after administration. </p>
<p>Ask your doctor or pharmacist for advice before taking any medicine. </p>
<p>Driving and using machines 
After Visudyne treatment you may have some vision problems, such as abnormal or decreased vision, 
which may be temporary. If this happens to you, do not drive or use any tools or machines until your 
vision improves. </p>
<p>Visudyne contains small amounts of butylated hydroxytoluene (E321) 
This ingredient is irritant to eyes, skin and mucous membranes. If you come into direct contact with 
Visudyne, you must therefore wash it off thoroughly with water. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take visudyne"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take visudyne"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Treatment with Visudyne is a two-step process </p>
<ul>
<li>
<p>First your doctor or the pharmacist will prepare the Visudyne infusion solution. It will be 
administered by your doctor or nurse into a vein using a drip (intravenous infusion). </p>
</li>
<li>
<p>The second step is the activation of Visudyne in the eye 15 minutes after the start of the 
infusion. Your doctor will put a special contact lens onto your eye and treat your eye using a 
special laser. It takes 83 seconds to deliver the laser dose required to activate Visudyne. During 
this time, you will have to follow your doctor s instructions and keep your eyes still. </p>
</li>
</ul>
<p>If necessary, Visudyne therapy can be repeated every 3 months, up to 4 times per year. </p>
<p>Use in children 
Visudyne is a treatment for adults only and not indicated for the use in children. </p>
<p>If you are given more Visudyne than you should be 
Overdose of Visudyne may prolong the time during which you are sensitive to light and you may need 
to follow the protection instructions given in section 2 for longer than 48 hours. Your doctor will 
advise you. </p>
<p>Overdose of Visudyne and light in the treated eye may result in severe vision decrease. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Some side effects could be serious: </p>
<p>Common (may affect up to 1 in 10 people) 
* Eye disorders: severe decrease of vision (loss of 4 lines or more within 7 days of treatment), 
visual disturbances such as blurred, hazy or fuzzy vision, flashes of light, decreased vision, and 
a change in the field of vision in the treated eye such as grey or dark shadows, blind spots or 
black spots. 
* General disorders: Hypersensitivity (allergic reactions), syncope (fainting), headache, light-
headedness, breathlessness. </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* Eye disorders: bleeding of the retina or into the vitreous humour (the clear gel-like substance 
that fills the eyeball behind the lens), swelling or fluid retention in the retina and displacement 
of the retina in the treated eye. 
* Infusion site side effects: as with other types of injections, some patients experienced bleeding 
at the infusion site, change in skin colour and hypersensitivity. If this happens to you, there will 
be increased sensitivity to light in that part of the skin until the green discolouration disappears. 
* General disorders: rash, hives, itching </p>
<p>Rare (may affect up to 1 in 1,000 people) 
* Eye disorders: lack of blood circulation to the retina or choroids (the vascular layer of the eye) 
in the treated eye. 
* General disorders: feeling unwell. </p>
<p>Not known (frequency cannot be estimated from the available data) 
* Eye disorders: tear in the coloured layer of the retina, swelling or fluid retention in the macula. 
* General disorders: vasovagal reactions (fainting), sweating, flushing, or changes in blood 
pressure. On rare occasions the vasovagal and hypersensitivity reactions may be severe and 
potentially include seizures. 
* Heart attack has been reported, particularly in patients with a history of heart disease, 
sometimes within 48 hours after treatment with Visudyne. In the event of suspected heart attack, 
seek medical attention immediately. 
* Localised death of skin tissue (necrosis). </p>
<p>If you experience any of these, tell your doctor straight away. </p>
<p>Other side effects: </p>
<p>Common (may affect up to 1 in 10 people) 
* Infusion site side effects: as with other types of injections, some patients experienced pain, 
swelling, inflammation, and weeping from the infusion site. 
* General disorders: feeling sick (nausea), sunburn-like reactions, tiredness, infusion-related 
reaction, primarily presented as chest pain or back pain, and increased cholesterol levels. </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* General disorders: pain, increased blood pressure, increased sensation, and fever. </p>
<p>Not known (frequency cannot be estimated from the available data) 
* Infusion site side effects: as with other types of injections, some patients experienced blistering. 
* General disorders: changes in heart rate. Infusion-related reaction, which may radiate to other 
areas, including but not limited to, the pelvis, shoulders or rib cage. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store visudyne"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store visudyne"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial after  EXP . The 
expiry date refers to the last day of that month. </p>
<p>Do not store above 25 C. Keep the vial in the outer carton in order to protect from light. </p>
<p>Chemical and physical in-use stability has been demonstrated for 4 hours at 25 C. From a 
microbiological point of view, the medicine should be used immediately. If not used immediately, the 
in-use storage time and conditions prior to use are the responsibility of the user and would normally 
not last longer than 4 hours below 25 C protected from light. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Visudyne contains 
- The active substance is verteporfin. Each vial contains 15 mg of verteporfin. After 
reconstitution, 1 ml contains 2 mg of verteporfin. 7.5 ml of reconstituted solution contains 
15 mg of verteporfin. 
- The other ingredients are dimyristoyl phosphatidylcholine, egg phosphatidylglycerol, ascorbyl 
palmitate, butylated hydroxytoluene (E321) and lactose monohydrate. </p>
<p>What Visudyne looks like and contents of the pack 
Visudyne is supplied as a dark green to black powder in a clear glass vial. The powder is reconstituted 
in water prior to use to form an opaque dark green solution. </p>
<p>Visudyne is available in packs containing 1 vial of powder. </p>
<p>Marketing Authorisation Holder 
CHEPLAPHARM Arzneimittel GmbH 
Ziegelhof 17489 Greifswald 
Germany </p>
<p>Manufacturer 
Delpharm Huningue S.A.S. 
26 rue de la Chapelle 
68330 Huningue 
France </p>
<p>CHEPLAPHARM Arzneimittel GmbH 
Ziegelhof 23-17489 Greifswald 
Germany </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu 
The following information is intended for healthcare professionals only: </p>
<p>Reconstitute Visudyne in 7.0 ml water for injections to produce 7.5 ml of a 2.0 mg/ml solution. 
Reconstituted Visudyne is an opaque dark green solution. It is recommended that reconstituted 
Visudyne be inspected visually for particulate matter and discoloration prior to administration. For a 
dose of 6 mg/m2 body surface (the dose recommended for the treatment) dilute the required amount of 
Visudyne solution in dextrose 50 mg/ml (5 %) solution for infusion to a final volume of 30 ml. Do not 
use sodium chloride solution. Use of a standard infusion line filter with hydrophilic membranes (such 
as polyethersulfone) of a pore size of not less than 1.2  m is recommended. </p>
<p>For storage conditions, please see section 5 of this leaflet. </p>
<p>The vial and any unused portion of reconstituted solution should be discarded after single use. </p>
<p>If material is spilled, it should be contained and wiped up with a damp cloth. Eye and skin contact 
should be avoided. Use of rubber gloves and eye protection is recommended. Any unused medicine or 
waste material should be disposed of in accordance with local requirements. </p>         </div>"""      



Instance: composition-da-8a06156d853d45b0ba99d89b9f448d89
InstanceOf: CompositionUvEpi
Title: "Composition for visudyne Package Leaflet"
Description:  "Composition for visudyne Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mped801563fb8e34f1b3dd54789546d247)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - visudyne"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du får Visudyne 
3. Sådan anvendes Visudyne 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What visudyne is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What visudyne is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Visudyne 
Visudyne indeholder det aktive stof verteporfin, som aktiveres af laserlys i en behandling som kaldes 
fotodynamisk terapi. Når du får en infusion af Visudyne, fordeles lægemidlet i din krop via 
blodårerne, herunder blodkarrene bagerst i øjet. Når øjet belyses med laserlys, bliver Visudyne 
aktiveret. </p>
<p>Hvad bruges Visudyne til 
Visudyne bruges til behandling af den våde form af aldersrelateret makuladegeneration og patologisk 
nærsynethed. </p>
<p>Disse sygdomme fører til synstab. Synstab skyldes nye blodkar (choroidal neovaskularisering), der 
beskadiger nethinden (den lysfølsomme membran bagerst i øjet). Der findes to former for choroidal 
neovaskularisering: Klassisk og okkult. </p>
<p>Visudyne bruges overvejende til behandling af den klassiske choroidale neovaskularisering hos 
voksne med aldersrelateret makuladegeneration, og også til behandling af alle typer for choroidal 
neovaskularisering hos voksne med patologisk nærsynethed. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take visudyne"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take visudyne"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du bør ikke få Visudyne 
- hvis du er allergisk over for verteporfin eller et af de øvrige indholdsstoffer i Visudyne (angivet 
i punkt 6). 
- hvis du lider af porfyri (en sjælden stofskiftelidelse, som kan øge følsomheden over for lys). 
- hvis du har en hvilken som helst alvorlig leversygdom. 
Fortæl det til din læge, hvis noget af det ovenstående passer på dig. I givet fald må du ikke få 
Visudyne. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, før du får Visudyne 
- Hvis du oplever nogle infusions-relaterede problemer eller symptomer under eller efter 
behandlingen såsom brystsmerter, svedudbrud, svimmelhed, udslæt, åndenød, ansigtsrødme, 
uregelmæssig hjerterytme eller anfald, skal du straks fortælle det til din læge eller 
sygeplejerske. Det kan være, at infusionen skal stoppes, og din tilstand skal behandles 
omgående. Infusions-relaterede problemer kan også omfatte pludselig bevidstløshed. 
- Hvis du lider af leverproblemer eller blokering af galdegangen, skal du fortælle det til din 
læge før behandling med Visudyne. 
- Hvis Visudyne kommer udenfor venen under infusionen, og især hvis det berørte område 
udsættes for lys, kan der opstå smerte, hævelse, blærer og misfarvning af huden omkring 
injektionsstedet. Hvis dette sker, skal infusionen stoppes og huden afkøles med is. Beskyt 
derefter huden mod lys indtil misfarvningen er forsvundet. Om nødvendigt kan smertestillende 
lægemiddel anvendes. 
- Du vil være følsom overfor skarpt lys i 48 timer efter infusionen. Indenfor de 48 timer, 
undgå at blive udsat for direkte sollys, kraftig indendørsbelysning såsom solarium, halogenlys, 
operationslys anvendt af læger og tandlæger eller lys fra medicinsk udstyr, f.eks. et 
pulsoximeter (bruges til at måle iltindholdet i blodet). Hvis du skal være ude i dagslys i denne 
periode skal du beskytte dine øjne og hud ved at bære mørke solbriller og dækkende tøj. 
Solcremer yder ingen beskyttelse. Normal indendørsbelysning er sikker. 
- Ophold dig ikke i mørke, da ophold i normal indendørsbelysning vil medvirke til at Visudyne 
hurtigere udskilles af kroppen. 
- Hvis du efter behandlingen får øjenproblemer, såsom synstab skal du kontakte din læge. </p>
<p>Brug af anden medicin sammen med Visudyne 
Fortæl altid lægen, sundhedspersonalet eller apotekspersonalet, hvis du bruger anden medicin eller har 
gjort det for nylig. </p>
<p>Fortæl din læge eller apotekspersonalet, hvis du bruger nogen af følgende lægemidler, da de kan 
forøge din lysfølsomhed:</p>
<ul>
<li>Tetracykliner eller sulfonamider (bruges til at behandle bakterielle infektioner), </li>
<li>Fenothiazider (bruges til at behandle psykiske lidelser eller kvalme og opkastning), </li>
<li>Sulfonylurinsyre (bruges til at behandle sukkersyge), </li>
<li>Lægemidler til at nedsætte blodsukkeret, </li>
<li>Thiaziddiuretika (bruges til at nedsætte højt blodtryk), </li>
<li>Griseofulvin (bruges til at behandle svampeinfektion), </li>
<li>Calciumantagonister (bruges til at behandle forhøjet blodtryk, hjertekrampe (angina) og 
unormal hjerterytme), </li>
<li>Antioxidanter såsom beta-caroten eller lægemidler, som kan fjerne eller inaktivere frie radikaler 
(såsom dimethylsulfoxid (DMSO), formiat, mannitol og alkohol), </li>
<li>Vasodilatorer (bruges til at udvide blodkarrene ved afslapning af den glatte muskulatur), </li>
<li>Eller hvis du får strålebehandling. </li>
</ul>
<p>Graviditet og amning 
- Der er meget lidt erfaring med Visudyne-behandling til gravide kvinder. Hvis du er gravid, har 
mistanke om du er gravid eller planlægger at blive gravid, er det vigtigt, at du informerer din 
læge. Visudyne bør kun anvendes, såfremt lægen vurderer, at det er absolut nødvendigt. 
- Verteporfin udskilles i små mængder i modermælk. Fortæl det til din læge, hvis du ammer. 
Lægen vil beslutte, om du skal behandles med Visudyne. Det anbefales, at du ikke ammer i 
48 timer efter en behandling med Visudyne. </p>
<p>Spørg din læge eller apotekspersonalet til råds, før du bruger nogen form for medicin. </p>
<p>Trafik- og arbejdssikkerhed 
Efter behandling med Visudyne, kan du få nogle synsproblemer, såsom unormalt eller nedsat syn, som 
kan være forbigående. Forekommer dette, må du ikke køre bil, arbejde med værktøj eller maskiner, før 
dit syn er blevet bedre. </p>
<p>Visudyne indeholder små mængder af butylhydroxytoluen (E321) 
Dette indholdsstof virker irriterende på øjne, hud og slimhinder. Hvis du kommer i direkte kontakt 
med Visudyne, skal du sørge for at skylle grundigt efter med vand. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take visudyne"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take visudyne"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Behandling med Visudyne er en to-trins-proces. </p>
<ul>
<li>
<p>Først tilberedes infusionsopløsningen med Visudyne af din læge eller apotek. Opløsningen vil 
blive givet af lægen eller sygeplejerskeren i et drop i en vene (intravenøs infusion). </p>
</li>
<li>
<p>Dernæst skal Visudyne aktiveres i øjet 15 minutter efter, at infusionen er begyndt. Din læge vil 
sætte en speciel kontaktlinse på dit øje og foretage behandlingen med en speciel laser. Det tager 
83 sekunder at give den laserdosis, som kræves for at aktivere Visudyne. Du skal i denne 
periode følge lægens instruktioner og holde øjet i ro. </p>
</li>
</ul>
<p>Hvis det er nødvendigt, kan behandlingen gentages hver 3. Måned op til 4 gange pr. år. </p>
<p>Brug til børn 
Visudyne er en behandling til voksne og er ikke beregnet til børn. </p>
<p>Hvis du får for meget Visudyne 
Overdosering af Visudyne kan forlænge tiden, hvor du er lysfølsom, og du kan blive nødt til at følge 
instruktionerne om beskyttelse i punkt 2 ud over de påkrævede 48 timer. Din læge vil give dig besked. </p>
<p>Overdosering af Visudyne og lys i det behandlede øje kan resultere i alvorlig synsnedsættelse. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Nogle bivirkninger kan være alvorlige: </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>Øjensygdomme: Alvorligt synstab (tab af 4 linier eller mere indenfor 7 dage efter behandling), 
synsforstyrrelser i det behandlede øje, såsom sløret, tåget eller uklart syn, lysglimt, nedsat syn 
og ændringer i synsfeltet såsom grå eller sorte skygger, blinde eller sorte pletter. </p>
</li>
<li>
<p>Almene symptomer: Overfølsomhed (allergiske reaktioner), besvimelse, hovedpine, 
svimmelhed, åndenød. </p>
</li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>Øjensygdomme: Nethindeblødning eller blødning i glaslegemet (den klare gelelignende 
substans som fylder øjeæblet bag ved linsen), hævelse eller ophobning af væske i nethinden og 
forskydning af nethinden i det behandlede øje. </p>
</li>
<li>
<p>Bivirkninger på infusionsstedet: Som med andre typer af infusioner oplever nogle patienter 
blødning på infusionsstedet, ændringer i hudfarve og overfølsomhed. Hvis du oplever dette, vil 
du være ekstra lysoverfølsom på hudområdet, indtil den grønne misfarvning forsvinder. </p>
</li>
<li>
<p>Almene symptomer: udslæt, nældefeber, kløe. </p>
</li>
</ul>
<p>Sjældne (kan forekomme hos op til 1 ud af 1.000 personer) </p>
<ul>
<li>
<p>Øjensygdomme: Manglende blodcirkulation til nethinden eller årehinden (øjets vaskulære lag) 
i det behandlede øje. </p>
</li>
<li>
<p>Almene symptomer: general utilpashed. </p>
</li>
</ul>
<p>Hyppighed ikke kendt (hyppighed kan ikke anslås ud fra tilgængelige data) </p>
<ul>
<li>
<p>Øjensygdomme: Rift i det farvede lag af nethinden, hævelse eller ophobning af væske i 
makula. </p>
</li>
<li>
<p>Almene symptomer: Vasovagale reaktioner (besvimelse), svedudbrud, ansigtsrødme eller 
ændringer i blodtryk. I sjældne tilfælde kan disse vasovagale og overfølsomhedsreaktioner være 
alvorlige, og de kan muligvis omfatte krampeanfald. </p>
</li>
<li>
<p>Hjerteanfald, særligt hos patienter med en sygehistorie med hjertesygdom, er blevet 
rapporteret indenfor 48 timer efter behandling med Visudyne. Hvis du har mistanke om et 
hjertetilfælde, skal du omgående søge lægehjælp. </p>
</li>
<li>
<p>Lokaliseret dødt hudvæv (nekrose) </p>
</li>
</ul>
<p>Hvis du oplever nogen af disse bivirkninger, skal du kontakte din læge med det samme. </p>
<p>Andre bivirkninger: </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>Bivirkninger på infusionsstedet: som ved andre injektioner oplever nogle patienter smerte, 
hævelse, irritation og sivning af væske fra infusionsstedet. </p>
</li>
<li>
<p>Almene symptomer: kvalme, reaktioner som ligner solskoldning, træthed, infusionsrelaterede 
reaktioner, først og fremmest brystsmerter eller rygsmerter, samt forhøjet kolesterol. </p>
</li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>Almene symptomer: smerte, forhøjet blodtryk, øget følsomhed, feber. </li>
</ul>
<p>Ikke kendt (kan ikke anslås ud fra tilgængelige data) </p>
<ul>
<li>
<p>Bivirkninger på infusionsstedet: som ved andre injektioner får nogle patienter blæredannelse. </p>
</li>
<li>
<p>Almene symptomer: ændringer i hjerterytmen (pulsen), infusionsrelaterede reaktioner, som 
kan stråle til andre steder, bl.a. men ikke begrænset til bækkenet, skuldrene eller brystkassen. </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store visudyne"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store visudyne"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på pakningen og hætteglasset efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25 °C. Opbevar hætteglasset i den ydre karton for at 
beskytte mod lys. </p>
<p>Prøver har vist at den færdige infusionsvæske er kemisk/fysisk stabil i op til 4 timer ved 25°C. Set fra 
en mikrobiologisk synsvinkel bør lægemidlet anvendes straks. Anvendes infusionsvæsken ikke straks, 
har brugeren ansvar for opbevaringsbetingelser og holdbarhedstid, som ikke bør overskride 4 timer, 
opbevaret under 25°C og beskyttet mod lys. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Visudyne indeholder:</p>
<ul>
<li>Aktivt stof: verteporfin. Hvert hætteglas indeholder 15 mg verteporfin. Efter rekonstitution 
indeholder 1 ml 2 mg verteporfin. 7,5 ml rekonstitueret infusionsvæske indeholder 15 mg 
verteporfin. </li>
<li>Øvrige indholdsstoffer: dimyristoyl phosphatidylcholin, ægphosphatidylglycerol, 
ascorbylpalmitat, butylhydroxytoluen (E321) og laktosemonohydrat. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Visudyne leveres som et mørkegrønt til sort pulver i et klart hætteglas. Pulveret rekonstitueres i vand 
umiddelbart før brug og danner en uigennemsigtig mørkegrøn opløsning. </p>
<p>Visudyne forhandles i pakninger indeholdende 1 hætteglas med pulver. </p>
<p>Indehaver af markedsføringstilladelsen 
CHEPLAPHARM Arzneimittel GmbH 
Ziegelhof 17489 Greifswald 
Tyskland </p>
<p>Fremstiller 
Delpharm Huningue S.A.S. 
26 rue de la Chapelle 
68330 Huningue 
Frankrig </p>
<p>CHEPLAPHARM Arzneimittel GmbH 
Ziegelhof 23-17489 Greifswald 
Tyskland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu 
Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Rekonstituer Visudyne i 7,0 ml vand til injektionsvæsker. Herved opnås 7,5 ml opløsning 
indeholdende 2 mg/ml. Rekonstitueret Visudyne er en uigennemsigtig mørkegrøn opløsning. Det 
anbefales, at rekonstitueret Visudyne inspiceres visuelt for partikler og misfarvning umiddelbart før 
anvendelse. For at få en dosis på 6 mg/m² legemsoverflade (den anbefalede behandlingsdosis) 
fortyndes den nødvendige mængde Visudyneinfusionsvæske med glucoseinfusionsvæske 50 mg/ml 
(5%) til et endeligt volumen på 30 ml. Anvend ikke natriumchloridinfusionsvæske. Brug af 
infusionsfilter med hydrofil membran (såsom polyethersulfon) med en porestørrelse af mindst 1,2 µm 
anbefales. </p>
<p>Opbevaringsbetingelser, se punkt 5 i denne indlægsseddel. </p>
<p>Hætteglasset og ethvert overskud af den rekonstituerede infusionsvæske skal kasseres efter endt brug. </p>
<p>Hvis materialet spildes, skal det tørres op med en fugtig klud. Øjen- og hudkontakt bør undgås. Brug 
af gummihandsker og øjenbeskyttelse anbefales. Ikke anvendt lægemiddel samt affald heraf skal 
bortskaffes i henhold til lokale retningslinjer. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8a06156d853d45b0ba99d89b9f448d89
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for visudyne Package Leaflet for language en"
Description: "ePI document Bundle for visudyne Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8a06156d853d45b0ba99d89b9f448d89"
* entry[0].resource = composition-en-8a06156d853d45b0ba99d89b9f448d89

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8a06156d853d45b0ba99d89b9f448d89"
* entry[=].resource = mp8a06156d853d45b0ba99d89b9f448d89
                            
                    
Instance: bundlepackageleaflet-da-8a06156d853d45b0ba99d89b9f448d89
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for visudyne Package Leaflet for language da"
Description: "ePI document Bundle for visudyne Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8a06156d853d45b0ba99d89b9f448d89"
* entry[0].resource = composition-da-8a06156d853d45b0ba99d89b9f448d89

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8a06156d853d45b0ba99d89b9f448d89"
* entry[=].resource = mp8a06156d853d45b0ba99d89b9f448d89
                            
                    



Instance: mp8a06156d853d45b0ba99d89b9f448d89
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Visudyne 15 mg powder for solution for infusion"
Description: "Visudyne 15 mg powder for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/00/140/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Visudyne 15 mg powder for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 8a06156d853d45b0ba99d89b9f448d89ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "visudyne"

* status = #current
* mode = #working

* title = "List of all ePIs associated with visudyne"

* subject = Reference(mped801563fb8e34f1b3dd54789546d247)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#visudyne "visudyne"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8a06156d853d45b0ba99d89b9f448d89) // visudyne en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8a06156d853d45b0ba99d89b9f448d89) // visudyne da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8a06156d853d45b0ba99d89b9f448d89
InstanceOf: List

* insert 8a06156d853d45b0ba99d89b9f448d89ListRuleset
    